Extravasation of antineoplastic agents: a practical drug-by-drug guide for the clinical oncologist

Extravasation is defined as the inadvertent leakage of an antineoplastic drug from the vascular compartment into surrounding tissues. Although uncommon, it is a potentially serious complication of systemic anticancer therapy. Reported frequencies vary substantially because studies use different populations, vascular devices, and chemotherapy regimens. Unrecognized vesicant extravasation can cause skin necrosis, tendon or nerve injury, and therefore functional impairment and a need for reconstructive surgery or interruption of cancer treatment. This narrative review provides a practical, drug-by-drug reference for clinical oncologists and multidisciplinary infusion teams. We address related definitions, prevention, risk factors, clinical presentation, differential diagnosis, severity assessment, drug classification, and immediate management suggestions. We discuss four commonly recommended antidotes — dexrazoxane, dimethyl sulfoxide, hyaluronidase, and sodium thiosulfate — focusing on indications, formulations, dosing schedules, and evidence-based medicine (EBM) limitations. Additionally, we cover delayed presentation, central venous access devices, immune checkpoint inhibitors, unconjugated monoclonal antibodies, antibody–drug conjugates, wound care, referral, documentation, and staff training. Because much of the evidence is observational and recommendations differ for several agents, treatment should follow a current, pharmacy-approved, drug-specific institutional protocol. Prompt recognition, avoidance of flushing, timely administration of the appropriate antidote, and structured follow-up remain central to limiting injury after extravasation.

Authors

Institutions

Publication Details

Journal
Nowotwory Journal of Oncology
Published
2026-11-13
DOI
https://doi.org/10.5603/njo.115646
Primary Topic
Chemotherapy-related skin toxicity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Extravasation of antineoplastic agents: a practical drug-by-drug guide for the clinical oncologist

Anna Brodziak, Kinga Bojarczuk, Marta Roszkowska, Andrzej Kawecki et al.
1 links
Nowotwory Journal of Oncology
Chemotherapy-related skin toxicity
article

Extravasation of antineoplastic agents: a practical drug-by-drug guide for the clinical oncologist

Anna Brodziak, Kinga Bojarczuk, Marta Roszkowska, Andrzej Kawecki, Anna Malgorzata Czarnecka, Maryna Rubach, Maciej Jerzy Krzakowski, Robert Dziura, Bożena Cybulska-Stopa, Marzena Puchała, Jerzy Piotrowski, Jerzy Turliński
article en

Abstract

Extravasation is defined as the inadvertent leakage of an antineoplastic drug from the vascular compartment into surrounding tissues. Although uncommon, it is a potentially serious complication of systemic anticancer therapy. Reported frequencies vary substantially because studies use different populations, vascular devices, and chemotherapy regimens. Unrecognized vesicant extravasation can cause skin necrosis, tendon or nerve injury, and therefore functional impairment and a need for reconstructive surgery or interruption of cancer treatment. This narrative review provides a practical, drug-by-drug reference for clinical oncologists and multidisciplinary infusion teams. We address related definitions, prevention, risk factors, clinical presentation, differential diagnosis, severity assessment, drug classification, and immediate management suggestions. We discuss four commonly recommended antidotes — dexrazoxane, dimethyl sulfoxide, hyaluronidase, and sodium thiosulfate — focusing on indications, formulations, dosing schedules, and evidence-based medicine (EBM) limitations. Additionally, we cover delayed presentation, central venous access devices, immune checkpoint inhibitors, unconjugated monoclonal antibodies, antibody–drug conjugates, wound care, referral, documentation, and staff training. Because much of the evidence is observational and recommendations differ for several agents, treatment should follow a current, pharmacy-approved, drug-specific institutional protocol. Prompt recognition, avoidance of flushing, timely administration of the appropriate antidote, and structured follow-up remain central to limiting injury after extravasation.

Nowotwory Journal of Oncology
Wrocław University of Science and Technology (PL), Medical University of Warsaw (PL), Holy Cross University (PL), The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Good health and well-being
Chemotherapy-related skin toxicity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon